The vertex cover problem seeks a minimum-cardinality set of vertices in a graph such that every edge is incident to at least one selected vertex. As an NP-hard combinatorial optimisation challenge, it ...

Vertex reported a phase 3 win for its kidney disease prospect povetacicept, meeting analyst expectations and firing the starting gun on a race to the FDA that could result in an accelerated approval ...

Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetacicept in IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Vertex said Monday that a drug it secured ...

Cystic fibrosis (CF) specialist Vertex is tracking two newer launches that speak to its efforts to expand its prowess beyond those roots. Despite mixed early results for those rollouts so far, the ...

A Book Review art director selects the book jackets that surprised him, delighted him and stayed with him this year. A Book Review art director selects the book jackets that surprised him, delighted ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big PBMs to cover the non-opioid pain drug. In what analysts called a “sticker ...

NEW YORK – A federal district court has ruled against Vertex Pharmaceuticals, thwarting its quest to provide fertility preservation treatment to patients receiving its gene-editing therapy through a ...